We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Therapeutic Antibodies – News and Features

News

BioWa and OncoTherapy Collaborate to Develop Anticancer Monoclonal Antibodies

OncoTherapy and BioWa will apply their technologies for the enhancement of antibody-dependent cellular cytotoxicity.
News

Roche and Epitomics Enter Into Monoclonal Antibody Technology Research Agreement

Agreement will help in the discovery and development of monoclonal antibodies to treat cancer and other diseases.
News

Immune Therapy Could Treat Leukemias, Autoimmune Diseases and Transplant Rejection

Monoclonal antibody has shown promise for treating leukemias, autoimmune diseases and transplant rejection.
News

MorphoSys Starts Multiple Antibody Programs with Schering

MorphoSys announces the start of a further three therapeutic antibody programs within the scope of its collaboration with Schering.
News

BioArctic and Abmaxis to Collaborate on Treatment for Alzheimer's Disease

Using its antibody technology, Abmaxis will further optimize and humanize BioArctic's murine antibodies.
News

FDA Approves BioGenex InSite™ HER-2/neu (CB11) Monoclonal Antibody

This antibody is used in tests to identify breast cancer patients eligible for treatment with the cancer drug Herceptin®.
News

Co-Development Partnership for Anti-Cancer Programme

The programme of two phases aims to initially validate CellCentric’s epigenetic-related lead cancer target, and subsequently develop monoclonal antibody therapeutic products.
News

MorphoSys Announces Cross Licensing of Technologies with Lilly

MorphoSys receives a license under the Kauffman patent estate to generate and screen certain recombinant peptide and protein libraries and to commercialize any resulting products.
News

Agreement to License UltiMAb Human Antibody Development System®

ImClone Systems intends to use the UltiMAb® system to develop human antibody product candidates against its disease targets, which are primarily in the area of oncology.
News

Collaboration to Develop Monoclonal Antibodies Targeting Cancer

MedImmune will be responsible for the clinical development and commercialization of any resulting products whereas VasGene will provide research and development support.
Advertisement